AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

The oral HER2 inhibitor zongertinib benefited patients with previously treated, HER2-mutated non-small cell lung cancer in a phase I clinical trial, according to results presented by John V. Heymach, ...

who have the relatively rare human epidermal growth factor receptor 2 (HER2)- mutations within the tyrosine kinase domain (TKD). At this year’s American Association for Cancer Research (AACR ...